Cocrystal Pharma
Cocrystal Pharma is a clinical-stage biotechnology company developing novel antiviral therapeutics using a structure-based drug discovery platform and Nobel Prize-winning expertise.
Company Overview
Cocrystal Pharma is a clinical-stage biotechnology company dedicated to developing novel antiviral therapeutics. The company's focus is on addressing the global need for effective and safe antiviral treatments through its unique structure-based drug discovery technology platform. By employing Nobel Prize-winning expertise, Cocrystal Pharma aims to create antiviral drugs that target the replication process of viruses such as influenza, SARS-CoV-2, hepatitis C, and norovirus.
Antiviral Development Programs
Cocrystal Pharma is advancing multiple programs with clinical development underway for several chronic and serious viral diseases including influenza, COVID-19, hepatitis C, and gastroenteritis caused by norovirus. The company is conducting multiple clinical trials, such as a Phase 2a human challenge trial for an oral PB2 inhibitor targeting pandemic and seasonal influenza A, and a Phase 1 study for a dual coronavirus-norovirus oral antiviral. Their program portfolio also includes a novel PB2 influenza A inhibitor and protease inhibitors targeting coronaviruses and noroviruses.
Structure-Based Drug Discovery
Cocrystal Pharma leverages a unique structure-based drug discovery technology platform to create novel antiviral compounds. This platform allows the company to design broad-spectrum replication inhibitors and other targeted antiviral therapeutics. Using this technology, Cocrystal Pharma is developing inhibitors of RNA-dependent RNA polymerase and protease for norovirus, as well as non-nucleoside polymerase inhibitors for hepatitis C. The company also actively works on discovering pan-viral inhibitors for respiratory viruses.
Clinical Trials and Research
Cocrystal Pharma's clinical trials include a Phase 2a human challenge study in the UK evaluating the safety and efficacy of an oral influenza A PB2 inhibitor, and preparations for a Phase 1 study in Australia to test an inhaled PB2 inhibitor as a treatment and prophylaxis for influenza A. The company is also conducting preclinical development of replication inhibitor compounds for influenza types A and B. In the realm of coronavirus research, Cocrystal Pharma is pursuing a program focused on developing broad-spectrum replication inhibitors.
Financial Information
As of March 31, 2024, Cocrystal Pharma reported unrestricted cash reserves of $21.8 million and working capital amounting to $22.1 million. The company had 10.2 million common shares outstanding. This financial standing supports the company's ongoing research and development initiatives in antiviral therapeutics.